Search - tctmd.com

Displaying 21 - 40 of 90

Sort: Relevancy | Date

News Conference News HFSA 2022

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

Todd Neale

October 04, 2022

News Opinion CV Team Dispatch

October 2022 News Roundup

L.A. McKeown

October 01, 2022

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

L.A. McKeown

September 23, 2022

Presentation TCT 2022

Moving Beyond Pharmacotherapy: The Transformative Role of Devices in HF Treatment

Presenter: William Abraham

September 16, 2022

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

News Daily News

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

Caitlin E. Cox

September 09, 2022

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

Todd Neale

August 27, 2022

News Conference News ESC 2022

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

L.A. McKeown

August 27, 2022

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

News Conference News ESC 2022

No Hints of Cognitive Defects With ARNIs in HFpEF: PERSPECTIVE

Shelley Wood

August 26, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

After COVID-19, Unvaccinated at Risk for Long-term CVD Complications

Michael O'Riordan

August 16, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2022

Todd Neale

August 01, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Daily News

US Dobutamine Shortage a ‘Huge Problem’—What’s the Solution?

Shelley Wood

July 15, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2022

Caitlin E. Cox

July 04, 2022

News Opinion CV Team Dispatch

July 2022 News Roundup

L.A. McKeown

July 01, 2022

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

L.A. McKeown

June 21, 2022

News Features

Risking COVID-19 for Professional Gain? Spring’s In-Person Meetings in Hindsight

Yael L. Maxwell

June 16, 2022

Advertisement

Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER

October 2022 News Roundup

Most Patient-Reported Outcome Measures in CVD Fall Short

Moving Beyond Pharmacotherapy: The Transformative Role of Devices in HF Treatment

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Older Adults See Rebound in Rates of HF-Related Death: CDC Data

CV Care Around Noncardiac Surgery: New ESC Guidelines

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

No Hints of Cognitive Defects With ARNIs in HFpEF: PERSPECTIVE

What’s Going to Be Hot at ESC 2022?

After COVID-19, Unvaccinated at Risk for Long-term CVD Complications

TCTMD’s Top 10 Most Popular Stories for July 2022

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

US Dobutamine Shortage a ‘Huge Problem’—What’s the Solution?

TCTMD’s Top 10 Most Popular Stories for June 2022

July 2022 News Roundup

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

Risking COVID-19 for Professional Gain? Spring’s In-Person Meetings in Hindsight

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content